CTKB Cytek Biosciences
- 6.410
- -0.280-4.19%
- 6.410
- 0.0000.00%
Cytek Biosciences News
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Busque Philippe
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Barnett Valerie
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Jiang Wenbin
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Poirson Allen
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Yan Ming
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Holder Michael
Cytek Biosciences | SC 13G: Statement of acquisition of beneficial ownership by individuals-Hillhouse Investment Management, Ltd.(5.1%)
Cytek Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Brown Capital Management, LLC(7.22%)
Cytek Biosciences | 10-Q: Q3 2024 Earnings Report
Cytek Biosciences | 8-K: Cytek Biosciences Reports Third Quarter 2024 Financial Results
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Jiang Wenbin
Cytek Biosciences | 8-K: Current report
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Holder Michael
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Barnett Valerie
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Jiang Wenbin
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Yan Ming
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Williams Paul Christopher
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Poirson Allen
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Busque Philippe
Cytek Biosciences | 10-Q: Q2 2024 Earnings Report
Analysis
Price Target
No Data
No Data